Previous 10 | Next 10 |
2023-03-13 12:54:16 ET Gainers: Provention ( PRVB ) +258% . Euda Health ( EUDA ) +41% . Calliditas ( CALT ) +31% . Cipher Mining ( CIFR ) +29% . Caleminder ( CMND ) +26% . Bakkt ( BKKT ) +26% . Hut 8 Mining ( HU...
2023-03-13 10:02:38 ET Gainers: Provention Bio PRVB +248% . Caleminder ( CMND ) +38% . Calliditas Therapeutics ( CALT ) +32% . Euda Health ( EUDA ) +22% . Seagen ( SGEN ) +15% . Losers: Cingulate CING -28...
2023-03-13 08:57:19 ET First Republic FRC -64% amid woes regarding SVB, Signature collapse . Western Alliance WAL -54% amid woes regarding SVB, Signature collapse . PacWest PACW -40% amid woes regarding SVB, Signature collapse . Euda Health ( EUDA...
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that the first patient has been...
Clinical stage global biopharmaceutical company focused on developing innovative cancer therapies, BeyondSpring ( NASDAQ: BYSI ) received a written notification from Nasdaq that the company has regained compliance with the minimum bid price requirement. Nasdaq has determined ...
NEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that on December 29, 2022, the C...
BeyondSpring ( NASDAQ: BYSI ) is trading ~18% higher after the company announced positive data from trial of lead asset, plinabulin, to prevent docetaxel-induced neutropenia in non-small cell lung cancer (NSCLC) patients. The analyses showed the efficacy of plinabulin as a mon...
Additional analyses of non-small cell lung cancer (NSCLC) studies support the efficacy of plinabulin monotherapy in reducing the mean duration of severe neutropenia (DSN) for patients receiving docetaxel In an analysis of breast cancer patients, plinabulin monotherapy was superior vs no...
NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that on November 18, 2022,...
NEW YORK, Sept. 13, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who ...
News, Short Squeeze, Breakout and More Instantly...
COPT Defense Properties of Beneficial Interest (CDP) is expected to report $0.64 for Q2 2024 Bank of Marin Bancorp (BMRC) is expected to report $0.19 for Q2 2024 Oak Ridge Financial Services Inc (BKOR) is expected to report for Q2 2024 D/B/A Centerspace (CSR) is expected to report $1....
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) rose 12.4% to $0.0886 on volume of 1,366,648,994 shares Ascent Solar Technologies Inc (ASTI) rose 63.4% to $0.2147 on volume of 656,794,712 shares Pineapple Energy Inc. (PEGY) rose 61.4% to $...
FLORHAM PARK, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that it hosted a virtua...